AVALO THERAPEUTICS INC (AVTX)
US05338F3064 - Common Stock
Taking everything into account, AVTX scores 3 out of 10 in our fundamental rating. AVTX was compared to 588 industry peers in the Biotechnology industry. AVTX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. While showing a medium growth rate, AVTX is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
In the past year AVTX has reported negative net income.
AVTX had a negative operating cash flow in the past year.
AVTX had negative earnings in each of the past 5 years.
AVTX had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of -150.28%, AVTX is doing worse than 86.01% of the companies in the same industry.
AVTX has a worse Return On Equity (-431.93%) than 78.33% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -150.28% | ||
| ROE | -431.93% | ||
| ROIC | N/A |
ROA(3y)-126.77%
ROA(5y)-113.98%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
AVTX's Gross Margin of 32.73% is fine compared to the rest of the industry. AVTX outperforms 77.82% of its industry peers.
AVTX's Gross Margin has declined in the last couple of years.
AVTX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 32.73% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-29.65%
GM growth 5Y-9.11%
2. Health
2.1 Basic Checks
AVTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for AVTX has been reduced compared to 1 year ago.
Compared to 5 years ago, AVTX has less shares outstanding
There is no outstanding debt for AVTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
AVTX has an Altman-Z score of -25.01. This is a bad value and indicates that AVTX is not financially healthy and even has some risk of bankruptcy.
AVTX has a Altman-Z score of -25.01. This is amonst the worse of the industry: AVTX underperforms 89.25% of its industry peers.
There is no outstanding debt for AVTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -25.01 |
ROIC/WACCN/A
WACC11.58%
2.3 Liquidity
A Current Ratio of 1.82 indicates that AVTX should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.82, AVTX is doing worse than 78.16% of the companies in the same industry.
AVTX has a Quick Ratio of 1.82. This is a normal value and indicates that AVTX is financially healthy and should not expect problems in meeting its short term obligations.
With a Quick ratio value of 1.82, AVTX is not doing good in the industry: 76.11% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.82 | ||
| Quick Ratio | 1.82 |
3. Growth
3.1 Past
The earnings per share for AVTX have decreased strongly by -92.94% in the last year.
The Revenue for AVTX has decreased by -89.30% in the past year. This is quite bad
AVTX shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -22.83% yearly.
EPS 1Y (TTM)-92.94%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q53.44%
Revenue 1Y (TTM)-89.3%
Revenue growth 3Y-34.03%
Revenue growth 5Y-22.83%
Revenue growth Q2Q-36.56%
3.2 Future
The Earnings Per Share is expected to grow by 15.09% on average over the next years. This is quite good.
The Revenue is expected to grow by 163.13% on average over the next years. This is a very strong growth
EPS Next Y96.49%
EPS Next 2Y40.17%
EPS Next 3Y25.25%
EPS Next 5Y15.09%
Revenue Next Year-29.41%
Revenue Next 2Y-23.3%
Revenue Next 3Y-16.21%
Revenue Next 5Y163.13%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for AVTX. In the last year negative earnings were reported.
Also next year AVTX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
AVTX's earnings are expected to grow with 25.25% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.17%
EPS Next 3Y25.25%
5. Dividend
5.1 Amount
No dividends for AVTX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
AVALO THERAPEUTICS INC
NASDAQ:AVTX (4/29/2024, 5:48:56 PM)
After market: 16.9 +0.02 (+0.12%)16.88
+0.94 (+5.9%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap17.39M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -150.28% | ||
| ROE | -431.93% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 32.73% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.09
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.82 | ||
| Quick Ratio | 1.82 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-92.94%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y96.49%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-89.3%
Revenue growth 3Y-34.03%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y